Entering text into the input field will update the search result below
Join now
Search for Symbols, analysts, keywords
Log in
ACET
Adicet Bio, Inc.
Latest News
Follow
$1.29
-0.02 (-1.15%)
4:00 PM 10/04/23
NASDAQ |
$USD |
Realtime
Summary
Ratings
Financials
Earnings
Dividends
Valuation
Growth
Profitability
Momentum
Peers
Options
Charting
All
Analysis
Comments
News
Transcripts
SEC Filings
Press Releases
Related Analysis
News
Show Full Stories
Show Full Stories
This feature available only for pro users
Type:
All Types
Date Range:
Select Date
Adicet Bio GAAP EPS of -$0.75 misses by $0.32
JMP downgrades Adicet to market perform, citing study delay
Biggest stock movers today: Unity Software, Walgreens Boots Alliance, Lordstown Motors and more
Adicet down 14% after hours on phase 1 data for non-Hodgkin's lymphoma asset
Adicet Bio falls as JPMorgan downgrades citing lack of catalysts
Adicet Bio GAAP EPS of -$0.72
Adicet Bio GAAP EPS of -$0.72 misses by $0.19
Adicet Bio plunges 38% after updating Phase 1 data for blood cancer therapy
Adicet shares drop ahead of updated Phase 1 data for blood cancer therapy
Adicet Bio GAAP EPS of -$0.53 in-line
Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Adicet Bio GAAP EPS of -$0.56 misses by $0.10
Adicet Bio updates Phase 1 data for CAR-T candidate in blood cancer
Adicet Bio gains after updating early-stage data for CAR-T therapy in blood cancer
Adicet Bio GAAP EPS of $0.10 beats by $0.30, revenue of $24.99M beats by $11.3M
Adicet Bio stock soars 13% on FDA fast track status for ADI-001 to treat blood cancer
Adicet Bio files for $500M mixed shelf offering
Adicet Bio GAAP EPS of -$0.47 misses by $0.05, revenue of $5.47M beats by $1.14M
Adicet Bio initiated Buy at Jefferies citing upcoming data readouts
Adicet Bio raises $87.5M through stock offering
Adicet Bio slips on common stock offering
Adicet posts early-stage data for off-the-shelf CAR-T therapy in Non-Hodgkin’s Lymphoma
Adicet Bio EPS beats by $0.01, beats on revenue
Adicet promotes head of research to chief scientific officer
ASND, GDS, ADSK and CDZI among after hours movers
Adicet Bio EPS beats by $0.19, beats on revenue
Adicet Bio joins Russell 2000 Index
Surface Oncology, Mustang Bio among top picks as BTIG turns bullish on cell and gene therapy space
Adicet Bio EPS misses by $0.31
Adicet Bio EPS beats by $0.42
Adicet Bio launches first-in-human study of ADI-001 in blood cancer
Adicet Bio shares down on $135M capital raise
Adicet Bio reports Q3 results
Adicet Bio on go with gamma delta T cell therapy in early-stage blood cancer study
Seeking Alpha Catalyst Watch
Adicet Bio will not go ahead with 4.5M-stock offering
Adicet Bio under pressure on launching equity offering
Adicet Bio appoints Nick Harvey as CFO
Nasdaq to delist two suspended medical companies
New Mountain Capital acquires ACETO's chemicals business
1
2
3
Next
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.